SARS-CoV-2 501Y.V2 escapes neutralization by South African COVID-19 donor plasma

dc.contributor.authorWibmer, Constantinos Kurt
dc.contributor.authorAyres, Frances
dc.contributor.authorHermanus, Tandile
dc.contributor.authorMadzivhandila, Mashudu
dc.contributor.authorKgagudi, Prudence
dc.contributor.authorOosthuysen, Brent
dc.contributor.authorLambson, Bronwen E.
dc.contributor.authorDe Oliveira, Tulio
dc.contributor.authorVermeulen, Marion
dc.contributor.authorVan der Berg, Karin
dc.contributor.authorRossouw, Theresa M.
dc.contributor.authorBoswell, Michael T.
dc.contributor.authorUeckermann, Veronica
dc.contributor.authorMeiring, Susan
dc.contributor.authorVon Gottberg, Anne
dc.contributor.authorCohen, Cheryl
dc.contributor.authorMorris, Lynn
dc.contributor.authorBhiman, Jinal N.
dc.contributor.authorMoore, Penny L.
dc.date.accessioned2021-04-07T07:26:39Z
dc.date.issued2021-04
dc.descriptionSupplementary Information: Supplementary Figs. 1 and 2en_ZA
dc.description.abstractSARS-CoV-2 501Y.V2 (B.1.351), a novel lineage of coronavirus causing COVID-19, contains substitutions in two immunodominant domains of the spike protein. Here, we show that pseudovirus expressing 501Y.V2 spike protein completely escapes three classes of therapeutically relevant antibodies. This pseudovirus also exhibits substantial to complete escape from neutralization, but not binding, by convalescent plasma. These data highlight the prospect of reinfection with antigenically distinct variants and foreshadows reduced efficacy of spike-based vaccines.en_ZA
dc.description.departmentImmunologyen_ZA
dc.description.departmentInternal Medicineen_ZA
dc.description.embargo2021-09-02
dc.description.librarianhj2021en_ZA
dc.description.sponsorshipThe South African Medical Research Council, the Wellcome Trust, US Centers for Disease Control and Prevention and the ELMA South Africa Foundation.en_ZA
dc.description.urihttp://www.nature.com/nmen_ZA
dc.identifier.citationWibmer, C.K., Ayres, F., Hermanus, T. et al. SARS-CoV-2 501Y.V2 escapes neutralization by South African COVID-19 donor plasma. Nature Medicine 27, 622–625 (2021). https://doi.org/10.1038/s41591-021-01285-x.en_ZA
dc.identifier.issn1078-8956 (print)
dc.identifier.issn1546-170X (online)
dc.identifier.other10.1038/s41591-021-01285-x
dc.identifier.urihttp://hdl.handle.net/2263/79329
dc.language.isoenen_ZA
dc.publisherSpringeren_ZA
dc.rights© The Author(s), under exclusive licence to Springer Nature America, Inc. 2021en_ZA
dc.subjectInfectious diseasesen_ZA
dc.subjectCOVID-19 pandemicen_ZA
dc.subjectCoronavirus disease 2019 (COVID-19)en_ZA
dc.subjectSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)en_ZA
dc.titleSARS-CoV-2 501Y.V2 escapes neutralization by South African COVID-19 donor plasmaen_ZA
dc.typePostprint Articleen_ZA

Files

Original bundle

Now showing 1 - 2 of 2
Thumbnail Image
Name:
Wibmer_SARSCoV2_2021.pdf
Size:
593.51 KB
Format:
Adobe Portable Document Format
Description:
Postprint Article
Download
Thumbnail Image
Name:
Wibmer_SARSCoV2Suppl_2021.pdf
Size:
6.19 MB
Format:
Adobe Portable Document Format
Description:
Supplementary Material
Download

License bundle

Now showing 1 - 1 of 1
Thumbnail Image
Name:
license.txt
Size:
1.75 KB
Format:
Item-specific license agreed upon to submission
Description:
Download

Collections

Research Articles (Internal Medicine)
Research Articles (Immunology)
Research Articles (University of Pretoria)
Simple item page